Ar­cutis scores FDA ap­proval for new foam treat­ment for com­mon skin con­di­tion

Cal­i­for­nia-based Ar­cutis Bio­ther­a­peu­tics on Fri­day won FDA ap­proval for a new foam-based skin treat­ment for se­b­or­rhe­ic der­mati­tis in in­di­vid­u­als 9 years of age and old­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER